Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wockhardt
ClinicalTrials.gov Identifier:
NCT01357603
First received: May 12, 2011
Last updated: January 24, 2013
Last verified: January 2013

May 12, 2011
January 24, 2013
June 2011
May 2012   (final data collection date for primary outcome measure)
  • Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h. [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
  • Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrs [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
  • Pharmacokinetic Parameters: Maximum concentration (Cmax) [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
Bioequivalence based on AUC INS-GLR 0-24h and AUC GIR 0-24h [ Time Frame: over 36hrs post dose ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01357603 on ClinicalTrials.gov Archive Site
  • Safety parameters [ Time Frame: till 24 hrs post-dose ] [ Designated as safety issue: Yes ]
    Number of AE's, SAE's, Hypoglycemic events and local tolerability
  • Pharmacodynamic parameters: Area under curve glucose infusion rate from 0-24hrs [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
    AUC GIR 0-12h,AUC GIR 12-24h,AUC GIR 0-24h
  • Pharmacokinetic parameter: Area under curve from 0-24hrs [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
    AUC INS-GLR 0-12hrs, AUC INS-GLR 12-24hrs,AUC INS-GLR 0-24hrs
  • Pharmacokinetic Parameters: tmax and t1/2 [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
  • Pharmacodynamic parameter: GIR max and tGIR max [ Time Frame: over 24hrs post dose ] [ Designated as safety issue: No ]
  • Safety parameters [ Time Frame: till 36 hrs post-dose ] [ Designated as safety issue: Yes ]
    Number of AE's, SAE's, Hypoglycemic events and local tolerability
  • Pharmacodynamic parameters: Area under curve glucose infusion rate from 0-36hrs [ Time Frame: over 36hrs ] [ Designated as safety issue: No ]
    AUC GIR 0-12h,AUC GIR 12-24h,AUC GIR 24-36h,AUC GIR 0-36h,AUC GIR 12-36hrs
  • Pharmacokinetic Parameters: Maximum concentration (Cmax) [ Time Frame: over 36hrs ] [ Designated as safety issue: No ]
  • Pharmacokinetic parameter: Area under curve from 0-36hrs [ Time Frame: over 36hrs ] [ Designated as safety issue: No ]
    AUC INS-GLR 0-12hrs, AUC INS-GLR 12-24hrs, AUC INS-GLR 24-36hrs, AUC INS-GLR 0-36hrs, AUC INS-GLR 12-36hrs
  • Pharmacokinetic Parameters: tmax and t1/2 [ Time Frame: over 36hrs ] [ Designated as safety issue: No ]
  • Pharmacodynamic parameter: GIR max and tGIR max [ Time Frame: over 36hrs ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes

The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.

The purpose of this study is to test for bioequivalence based on the pharmacokinetic parameter AUC INS-GLR 0-24h and on pharmacodynamic parameter AUC GIR 0-24h between the two long-acting insulin glargine formulations, Lantus® and Wockhardt's Glaritus® in subjects with type1 diabetes as well as assessing safety and local tolerability of the two insulin preparations.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Type1 Diabetes
Biological: Glargine
dosage form: Subcutaneous injection
  • Experimental: Glaritus arm
    Insulin glargine (Glaritus: 100 U/ml), Penfill® cartridges 3.0ml
    Intervention: Biological: Glargine
  • Active Comparator: Lantus arm
    Insulin glargine (Lantus: 100 U/ml), Penfill® cartridges 3.0ml
    Intervention: Biological: Glargine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
111
August 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female subjects with type 1 diabetes ≥12 months.
  2. HbA1c ≤9% by local laboratory analysis (one retest within a week is permitted with the result of the last test being conclusive).
  3. Age ≥18 and ≤60 years.
  4. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator.
  5. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject).

Exclusion Criteria:

  1. Previous participation in this trial, or participation in other clinical trials within the last 30 days.
  2. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (e.g. intrauterine device (IUD) that has been in place for at least 3 months, or sterilization, or the oral contraceptive pill, which should have been taken without difficulty for at least 3 months, an approved hormonal implant or double barrier method including male condoms used plus spermicide, diaphragm with spermicide plus male condom, cap with spermicide plus male condom).
  3. History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (hemoglobin below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.
  4. Cardiac problems defined as decompensated heart failure (New York Heart Association (NYHA) class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time.
  5. Clinically significant abnormal ECG at screening, as judged by the Investigator.
  6. History of alcohol or drug abuse in the past five years.
  7. Any positive reaction of drug abuse.
  8. Hepatitis B or C or HIV positive.
  9. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  10. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  11. Regular cigarette smoker, defined as smoking >1 pack/day and unable to refrain from smoking during the in house period.
  12. Known or suspected allergy to trial product or related products.
  13. Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01357603
Glaritus/PK-PD/FDA/2011
No
Wockhardt
Wockhardt
Not Provided
Principal Investigator: Dr. Elaine Watkins Profil Institute of Clinical Research
Wockhardt
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP